Contribution of Hepatitis B Contribution to Anemia in Dialysis Patients with Chronic Renal Failure, Iraq

Document Type : Original Articles

Authors

1 Department of Microbiology, College of Medicine, Ibn Sina University of Medical and Pharmaceutical Science, Baghdad, Iraq

2 Department of Biology, College of Science, Al-Qasim Green University, Al Qasim, Iraq

3 Department of Basic Medical Science, College of Nursing, University of Babylon, Babylon, Iraq

4 Consultant Urologist, College of Medicine, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq

Abstract

Chronic renal failure are caused by impaired kidney function; this organ is essential in the metabolism, filtration, and excretion of compounds. Human hepatitis B virus is common in dialysis patients with chronic renal failure, and chronic kidney disease (CKD) is also associated with anemia in dialysis patients. In this study, 50 (36 men and 14 women) dialysis patients from Imamian Al-Khademian city, with ages between 30 and 77 years, and a healthy group (control group) with ages ranging between 30 and 62 years, were evaluated. Detection of hepatitis B virus by a molecular technique of real-time PCR and the concentration of erythropoietin hormone detected by the ELISA technique. The results showed that the prevalence of dialysis patients aged 41–50 and 60–51 was 20% and 18%, respectively. The detection of Hepatitis B from the serum of dialysis patients' samples showed that HBV was seen in 15 (30%) of the 50 serum samples. The concentration of the erythropoietin hormone in dialysis patients’ samples was lower than in the healthy groups (a control group). Also, the concentration of erythropoietin hormone was significantly lower in dialysis patients compared with the control group (P>0.05). Hepatitis B can affect chronic renal failure and dialysis patients' immunity. Also, people with hepatitis B have a lower level of the erythropoietin hormone, which is a major cause of anemia in dialysis patients.

Keywords

References

  1. Anibijuwon I, Ojo O. Determination of Antibodies to Hepatitis B Virus in Pregnant Women in Akure; Ondo State; Nigeria. Cont J Microbiol. 2010.
  2. Moustafa S, Karakasiliotis I, Mavromara P. Hepatitis C virus core+ 1/ARF protein modulates the cyclin D1/pRb pathway and promotes carcinogenesis. J Virol. 2018;92(9):02036-17.
  3. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166(11):792-8.
  4. Bernieh B. Viral hepatitis in hemodialysis: An update. J Trans Intern Med. 2015;3(3):93-105.
  5. Rodriguez-Inigo E, Bartolome J, Ortiz-Movilla N, Platero C, Lopez-Alcorocho J, Pardo M, et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol. 2005;79(24):15578-81.
  6. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg‐negative patients: a study of a low‐endemic area. Hepatology. 1993;17(1):20-9.
  7. Branco F, Mattos AAd, Coral GP, Vanderborght B, Santos DE, França P, et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq Gastroenterol. 2007;44(1):58-63.
  8. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436(7053):961-6.
  9. Kaneko S, Feinstone SM, Miller RH. Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Microbiol. 1989;27(9):1930-3.
  10. Besisik F, Karaca C, Akyüz F, Horosanlı S, Önel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003;38(4):506-10.
  11. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine-and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001;8(3):237-47.
  12. Weinberger KM, Bauer T, Böhm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol. 2000;81(5):1165-74.
  13. Cabrerizo Ma, Bartolomé J, Caramelo C, Barril G, Carreño V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen–negative cases. Hepatology. 2000;32(1):116-23.
  14. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, et al. HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. Kidney Int. 1995;48(6):1967-71.
  15. Dumaidi K, Al‐Jawabreh A. Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine. J Med Virol. 2014;86(10):1694-9.
  16. El Makarem MAA, Hamid MA, Aleem AA, Ali A, Shatat M, Sayed D, et al. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon. 2012;12(4):253.
  17. Yakaryilmaz F, Alp Gurbuz O, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006;28(8):729-35.
  18. Cengiz C, Turhan N, Yolcu OF, Yılmaz S. Hepatitis associated with aplastic anemia: do CD8 (+) kupffer cells have a role in the pathogenesis? Dig Dis Sci. 2007;52(9):2438-43.
  1. Kolawole OM, Wahab AA, Adekanle DA, Sibanda T, Okoh AI. Seroprevalence of hepatitis B surface antigenemia and its effects on hematological parameters in pregnant women in Osogbo, Nigeria. Virol J. 2012;9(1):1-6.
  2. WHO. Iron deficiency anaemia. Assessment, prevention and control A guide for programme managers Geneva: World Health Organization (WHO); 2001.[cited May 2017 2016]. World Health Organization (WHO):[Available from: http://www who int/nutrition/publications/en/ida_assessment_prevention_control pdf[Google Scholar].
Archives of Razi Institute
Volume 77, Issue 5 - Serial Number 5
September and October 2022
Pages 1763-1767

Files

Share

How to cite

Statistics